TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698304

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
Study: NCT05142540

Intervention type: PROCEDURE
Intervention: blood and saliva samples will be taken
Description: For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit.~For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2.
Study: NCT04698304

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: All the patients are treated by endovascular therapy, through contralateral femoral artery approach, ipsilateral antegrade femoral artery approach or brachial artery approach. If the lesion is difficult to pass in antegrade approach, retrograde puncture at the distal artery of the lesion can be performed. Surgeons can choose treatment methods according to the characteristics of the lesions. For example: (a) Plain old balloon angioplasty; (b) Drug-coated balloon angioplasty; (c) Drug-coated balloon angioplasty + provisional stenting; (d) Bare-metal stent implantation; (e) Stent graft implantation; (f) Directional atherectomy + drug-coated balloon angioplasty, (g) Drug -eluting stent.
Study: NCT06419452

Intervention type: OTHER
Group type: OTHER
Intervention: Unilateral resistance training programme
Description: A method of training that increases muscle strength and endurance by using external resistance to a unilateral limb or movement.

Intervention type: OTHER
Group type: OTHER
Intervention: Bilateral resistance training programme
Description: A training method that increases muscle strength and endurance by using external resistance on both limbs or movements,

Intervention type: OTHER
Group type: OTHER
Intervention: Combined（UL+BL） resistance training programme
Description: A method of training that uses limbs or movements to increase muscle strength and endurance by external resistance using unilateral and bilateral combined forms,
Study: NCT05630430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures
Description: Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Effect of Volar Carbon Plate Applications on Radiation Exposure and Procedure Time in Intra-articular Radius Distal End Fractures
Description: Surgery procedure, Although the bones are at the surgeon's disposal in plate fixation of radius distal end fractures, fluoroscopy is frequently used for reduction control. The increase in the need for scopy both directly affects the duration of the operation and causes the surgical team to be exposed to excessive radiation. Since titanium alloy plates are radiopaque, they create a superposition to the fracture line and more than one view is usually required in each plane to ensure the reduction quality during surgery. Carbon alloy plates, on the other hand, offer the advantage of faster radiological reduction control because they do not create superposition to the fracture line. In our study, in addition to the comparisons in the literature, it is aimed to investigate the effect of carbon plates on the procedure time. surgery time and exposure of radiation will be recorded at the end of the surgery
Study: NCT00987233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide aqueous nasal spray (Apotex Inc.)
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study: NCT05906875

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Stepping Exercise 1
Description: 1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Stepping Exercise 1
Description: 1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Stepping Exercise 1
Description: 1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Stepping Exercise 1
Description: 1. Standing hip abduction: Performed without and with resistance bands and/or support. The participant will raise one leg out to the side and return. If using a resistance band, one end of the band will be secured to a stable surface and the other end placed around one of the participants' ankles. The banded leg will be raised to the side. Three sets of 8-12 repetitions will be performed per side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Control Group Exercise 1
Description: 1. Seated ankle movements (dorsi-/plantarflexion)hree sets of 8-12 repetitions will be performed per limb with the maintenance of end-range contraction of 6 seconds.
Study: NCT06528405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other anti-diabetic drug or no anti-diabetic drug
Description: Other anti-diabetic drug or no anti-diabetic drug for 90 days during the acute kidney disease period.~Other anti-diabetic drug includes metformin, sulfonylureas, meglitinides, dipeptidyl peptidase-4 inhibitor, insulin, α-glucosidase inhibitors, thiazolidinediones, and glucagon-like peptide-1 receptor agonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canagliflozin
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study: NCT00987233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
Study: NCT06107400

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RM-004
Description: Intravenous infusion of gene-edited CD34+autologous hematopoietic stem cells (RM-004) after myeloablative conditioning with busulfan.
Study: NCT05298696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily
Study: NCT05562024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting B7-H3 chimeric antigen receptor
Description: The subjects will be administered once.
Study: NCT05086289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3526318
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT05739812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telesurgery by domestic surgical robot
Description: telesurgery of urological diseases by domestic surgical robot
Study: NCT05452759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow oxygen therapy device for Severe pneumonia patients with artificial airway
Description: Using NTHF, adjust the MR850 humidifier to invasive automatic gear, the temperature sensor automatically adjusts and maintains the gas temperature at the entrance of the tracheal tube at 37°C according to the feedback temperature, and monitors and maintains SpO2 between 94% and 100%. The monitored pulse oxygen saturation (SpO2) is used to adjust the concentration of the venturi valve and the corresponding oxygen flow rate. At the preset gas flow rate levels of 40L/min, 50L/min and 60L/min, the test pipeline is connected to optimize the breath. The actual gas flow rate value and the gas flow rate loss difference before and after the gas joint (screw joint), and at the corresponding gas flow rate, measure the gas temperature and humidity at the near-patient end of the pipeline.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AIRVOTM2 device for Severe pneumonia patients with artificial airway
Description: Use AIRVOTM2 (Fisher \& Paykel, Auckland, New Zealand), select the output gas temperature of 37°C, monitor and maintain SpO2 between 94% and 100%, and adjust the output gas flow rate of the therapy device to 40L/min, 50L/min and 60L/min, respectively. min, measure the actual gas flow rate value and the gas flow rate loss difference before and after each flow rate horizontal pipeline is connected to the conventional exhalation joint (matching special exhalation joint), and measure the gas temperature and humidity near the patient end of the pipeline at the corresponding gas flow rate.
Study: NCT05351814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: While the patients will be exercised with a physiotherapist 1 day a week, the treatment will be followed as a home exercise program 2 days a week.
Study: NCT05695872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: subtarsal approach
Description: surgical approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional transconjunctival approach
Description: surgical approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transconjunctival approach with Y- modification
Description: surgical approach
Study: NCT05173597

Intervention type: DRUG
Intervention: Follitropin delta
Description: REKOVELLE® (follitropin delta), solution for injection - delivered with an injection pen, ATC code G03GA10, is a recombinant human FSH approved for the controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.
Study: NCT05876923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study: NCT05253274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Description: In addition to the routine practice of the emergency service, the virtual reality (VR) group will watch a video with VR glasses during the emergency surgical intervention under local anesthesia. Before the emergency surgery, the patients will be asked to wear a VR glasses compatible with mobile phones with android operating system and a headset that minimizes sound loss. Patients will be shown their preferred 3D licensed video software with relaxing music in the background. VR glasses will be put on the patients before starting the emergency surgical procedure under local anesthesia and applied until the procedure was completed. Patients will be asked to refill the The State Anxiety Inventory at the end of the emergency surgical intervention. At the same time, blood pressure, heart rate, respiratory rate, SpO2 values will be monitored on a portable monitor.
Study: NCT05667636

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: salvage SBRT
Description: steretactic body radiation therapy in the setting of salvage radiotherapy for prostate cancer
Study: NCT05876923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET
Study: NCT05876923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Exercise Testing
Description: Undergo CPET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual X-ray Absorptiometry
Description: Undergo DEXA scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo aerobic based training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Undergo aerobic based training program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs
Study: NCT04836819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain
Description: IV lidocaine infusion (2 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 1 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: IV ketamine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: IV dexmedetomidine infusion (0.5 mg/kg/h) will be initiated after anesthesia induction and decrease the dosage to 0.3 mg/kg/h at the end of surgery. The infusion will continue until 12 hours after the operation.1 g paracetamol, 100 mg tramadol, 100 mg ketoprofen, and 4 mg dexamethasone will be administered to all patients pre-emptively. Granisetron (3 mg) will be administered 30 minutes before the end of surgery. In the postoperative period, i.v. Paracetamol will be administered at 8-hour intervals and 25-50 mg meperidine i.m. (maximum dose 200 mg) as rescue analgesia when requested by the patient and if VAS\>4.
Study: NCT05876923

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Examination
Description: Undergo measurement of height/weight and vital signs

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06071299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FCC
Description: Children evaluated for abusive injuries. Caregiver offered meeting with IPV advocate during visit (survivor-centered care, immediate access to services; continued engagement with advocate for ongoing needs). Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CCC
Description: Children evaluated for abusive injuries. Medical provider offers IPV resources to caregiver. Referral to Child-Study center for trauma follow up. Connection to pediatrician. Use of motivational interviewing to address IPV.